Portal de Periódicos da CAPES

Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet Therapies

2014; American College of Physicians; Volume: 161; Issue: 5 Linguagem: Inglês

10.7326/l14-5017-6

1539-3704

Dhruv S. Kazi, Douglas K Owens, Mark A. Hlatky,

Pharmaceutical Economics and Policy

Letters2 September 2014Cost-Effectiveness of Genotype-Guided and Dual Antiplatelet TherapiesDhruv S. Kazi, MD, MSc, MS, Douglas K. Owens, MD, MS, and Mark A. Hlatky, MDDhruv S. Kazi, MD, MSc, MSFrom University of California, San Francisco, San Francisco, California; Veterans Affairs Palo Alto Healthcare System, Palo Alto, California; and Stanford University School of Medicine, Stanford, California.Search for more papers by this author, Douglas K. Owens, MD, MSFrom University of California, San Francisco, San Francisco, California; Veterans Affairs Palo Alto Healthcare System, Palo Alto, California; and Stanford University School of Medicine, Stanford, California.Search for more papers by this author, and Mark A. Hlatky, MDFrom University of California, San Francisco, San Francisco, California; Veterans Affairs Palo Alto Healthcare System, Palo Alto, California; and Stanford University School of Medicine, Stanford, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L14-5017-6 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Marciniak highlights some of the many sources of uncertainty about the choice of an antiplatelet agent for patients receiving percutaneous coronary intervention after ACS. Uncertainty in results of clinical research is common, which is precisely why a systematically and transparently designed simulation model is useful. We reviewed more than 100 publications, including publicly available FDA documents, to identify the most credible estimates of each parameter in the model. A key feature of the model is that, beyond the use of the single best estimate of key parameters (the “base case”), it explicitly assesses the effect of uncertainty ...References1. Basu S, Andrews J. Complexity in mathematical models of public health policies: a guide for consumers of models. PLoS Med. 2013;10:e1001540. [PMID: 24204214] doi:10.1371/journal.pmed.1001540 CrossrefMedlineGoogle Scholar2. Sainani KL. The problem of multiple testing. PM R. 2009;1:1098-103. [PMID: 20006317] doi:10.1016/j.pmrj.2009.10.004 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of California, San Francisco, San Francisco, California; Veterans Affairs Palo Alto Healthcare System, Palo Alto, California; and Stanford University School of Medicine, Stanford, California.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-1999. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUpdate in Rheumatology: Evidence Published in 2013 E. Blair Solow , Salahuddin Kazi , and Una E. Makris Metrics Cited byPersonalizing Antiplatelet Therapies for Acute Coronary Syndrome (ACS) in Patients Undergoing Percutaneous Coronary Intervention (PCI): Are They Cost-effective? 2 September 2014Volume 161, Issue 5Page: 378-379KeywordsAspirinDisclosureDrugsFood and Drug AdministrationGenotypingPercutaneous coronary interventionPharmacokineticsRandomized trialsSt segment elevation myocardial infarctionStatins ePublished: 2 September 2014 Issue Published: 2 September 2014 Copyright & PermissionsCopyright © 2014 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...